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Background: The interleukin (IL)18 rs360719 CC genotype is associated with the development of antibodies to
hepatitis B virus surface antigen (anti-HBs) in hemodialysis (HD) patients. IL18 shares biological properties with IL12
in promoting the T-hepler 1 (Th1) system. We studied whether polymorphisms in the IL12A 3` untranslated region
(UTR) and IL12B 3`UTR may contribute to anti-HBs development (titre ≥ 10 IU/L) in HD patients either individually or
jointly with the IL18 polymorphism.
Methods: In 518 HD patients and 240 controls the IL12A rs568408 3’UTR G>A polymorphism was genotyped by
high-resolution melting curve analysis. Polymerase chain reaction restriction fragment length polymorphism was
used to detect the IL12B rs3212227 3’UTR A> C and IL18 -1297 T > C rs360719 polymorphisms. The associations
between the IL12A, IL12B and IL18 genotypes and the risk of impaired anti-HBs development were estimated by
computing the odds ratios and their 95% confidence intervals using logistic regression analysis.
Results: In the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients
without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC
combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA
(p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients. Patients
bearing both rs568408 AA and rs360719 TT had a 10.9-fold or 8.9-fold lower chance, respectively, to develop
anti-HBs compared with those carrying any other genotype (p = 0.005) or those who had both wild-type rs568408
GG and rs360719 TT (p = 0.011). Carriers of both rs3212227 CC and rs360719 TC had a 4.6-fold lower chance for
anti-HBs development than carriers of any other genotype (p = 0.042).
Conclusion: Development of anti-HBs in HD patients is associated with gene polymorphisms of interleukins
involved in the Th1 system.
Keywords: Antibodies to surface antigen of hepatitis B virus, Gene polymorphisms, Hemodialysis, Interleukin 12,
Interleukin 18Background
Chronic kidney disease patients on intermittent
hemodialysis (HD) have been known to exhibit impaired
immune system function with regards to the formation
of antibodies against hepatitis B virus surface antigen
(anti-HBs). Cytokines, among them interleukin (IL) 12
and IL18, play a key role in the regulation of hepatitis B* Correspondence: alicja_grzegorzewska@yahoo.com
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distribution, and reproduction in any mediumvirus (HBV) clearance and the immune response to
HBV antigens during spontaneous natural infection [1-4]
or planned vaccination [5-9].
IL-12 is a heterodimeric cytokine formed by a 35,000
dalton (Da) light chain (known as p35) and a 40,000 Da
heavy chain (known as p40). The subunits p35 and p40
of IL12 are encoded by IL12A and IL12B, respectively,
which are located on separate chromosomes (3p12-q13.2
and 5q31-33). IL-18 is an 18,300 Da cytokine. The
human IL-18 gene is located on chromosome
11q22.2_q22.3. IL-12 shares biological properties withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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factor [10-13]. In mice, IL-12 p40 and IL-18 acted in
concert in a poxvirus infection [14]. In other studies
using IL12 p40−/− or IL18−/− mice, only IL-12 p40 or
IL-18 was important for defense against human viruses
adapted to the mouse [15,16]. In HD patients, the IL18
-1297CC rs360719 genotype, attributed to increased IL-
18 secretion [17], was recently connected with the devel-
opment of anti-HBs [18]. It is not known whether the
IL12 genotype is concomitantly associated with the IL18
genotype in the development of anti-HBs.
The aim of our study was to determine whether poly-
morphisms in IL12A and IL12B may individually or
jointly with the IL18 polymorphism contribute to anti-
HBs development in HD patients. We have demon-
strated that rs360719 CC individually and rs360719 CC
combined with rs568408 GG, rs568408 GA, rs568408
GG/AA or rs3212227 AA are associated with an
increased chance of developing anti-HBs in HD patients,
whereas combined rs568408 AA and rs360719 TT or
combined rs3212227 CC and rs360719 TC are asso-
ciated with a lower chance of anti-HBs development. In
HD the patients development of anti-HBs has been
shown to be associated with gene polymorphisms of IL
involved in the T-cell helper 1 (Th1) system.
Methods
Patients and controls
Studies were carried out in HD patients treated in 20
dialysis centers of the Wielkopolska region of Poland be-
tween February 11, 2009 and August 01, 2011. All
patients with negative HBV seromarkers were vaccinated
against HBV according to the standard rules for HD
patients (4 vaccine doses of 40 μg each were given at 0–
1–2–6 months) [19]; an anti-HBs titre was checked after
4–8 weeks from the last vaccine dose. An anti-HBs
titre > 10 IU/L is assumed to be protective in vaccinated
patients [20]. When an anti-HBs titre remained below
10 IU/L, vaccination against HBV was repeated. Due to
fluctuations of anti-HBs in HD patients, blood testing
for anti-HBs was repeated on a mandatory basis every
6 months to determine if vaccine booster doses were
required.
Patients enrolled to the study had to fulfill the follow-
ing criteria:
1. treatment with intermittent HD due to end-stage
renal disease,
2. no signs and symptoms of acute infection with
blood-borne viruses,
3. known anti-HBs titre (all available results of each
patient were analyzed),
4. in patients without serological signs of HBV
transmission, having an anti-HBs titre below 10 IU/L, two full vaccination series against HBV (4 doses
of 40 μg each given at 0–1–2–6 months) had to be
given or equivalent vaccine dosage had to be applied
and the patients` anti-HBs titre had to be
determined 4–8 weeks from the last vaccine dose,
5. from patients who disclosed a genetic relationship
only one person could participate in the study,
6. written consent to participate in the study.
A response to HBsAg after vaccination or natural
HBV transmission was considered to be positive when
an anti-HBs titre exceeded 10 IU/L.
The inclusion criteria were fulfilled by 518 HD
patients. These patients were divided into two groups
dependent on anti-HBs development. Responders devel-
oped anti-HBs, whereas non-responders did not develop
anti-HBs. Responders were the reference group for non-
responders.
Group I (HBsAg non-responders, n = 207) included
HD patients who did not develop an anti-HBs
titre > 10 IU/L in response to HBsAg from the HBV vac-
cine [patients with negative total antibodies to HBV core
antigen (anti-HBc), n = 177] or in response to HBsAg
transmitted during natural HBV infection (patients with
total anti-HBc positive, n = 30). The available medical
documents for these patients did not reveal any anti-
HBs > 10 IU/L.
Group II (HBsAg responders, n = 311) consisted of
HD patients who developed an anti-HBs titre >10 IU/
L as a result of vaccination (patients with total anti-
HBc negative, n = 213) or as a result of HBV trans-
mission (patients with total anti-HBc positive, n = 98).
In some patients with a long course of renal disease,
a history of vaccination effectiveness revealed periods
with or without anti-HBs > 10 IU/L. If a patient had
anti-HBs > 10 IU/L in the past but lost it during the
course of renal disease, she/he was considered as con-
stitutionally able to respond for HBsAg and was
included into group II.
Registered blood donors from the Wielkopolska region
of Poland (n = 240), qualified for blood donation accord-
ing to the criteria of Polish Ministry of Health [21],
served as controls for HD patients. The control persons
had serum alanine aminotransferase activity not higher
than 2 times the upper normal limit of the applied la-
boratory method. All controls showed negative blood
testing for HBsAg and HBV DNA as well as for sero-
markers of infection with the hepatitis C virus. Unfortu-
nately, the vaccination rate against HBV and an anti-
HBs titre were not known in these healthy individuals.
Genotype analysis for rs568408 3`UTR G>A in
IL12A, rs3212227 3`UTR A>C in IL12B and -1297 C/T
rs360719 in IL18 was done in all HD patients and
controls.
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HBsAg and anti-HBc were determined by Microparticle
Enzyme Immunoassay (MEIA) technology (AxSYM,
Abbott Laboratories, Abbott Park, USA). MEIA technol-
ogy (ABBOTT, Wiesbaden, Germany) was also used for
detection of anti-HBs and antibodies to hepatitis C virus
(anti-HCV). HBV DNA was determined using a qualita-
tive test COBAS AMPLICOR HBV MONITOR; HCV
RNA was tested using COBAS AMPLICOR Hepatitis C
Virus Test, version 2.0 (both Roche Diagnostics Ltd.,
Rotkreutz, Switzerland). Serum activities of liver enzymes
were determined by routine laboratory methods.
IL12A, IL12B and IL18 genotyping
DNA was isolated from peripheral leukocytes using a
standard salting out procedure.
The IL12A 3’UTR G>A (rs568408) DNA fragments
were amplified using primers 5’ ATGAGGAAACTTTGA
TAGGATG 3’ and 5’TTCCCTTCTTAGCAATTCATTC
3’. This polymorphism was then genotyped by high-
resolution melting curve analysis (HRM) using the Light
Cycler 480 system (Roche Diagnostics, Mannheim, Germany).
Identification of the IL12B 3’UTR A>C (rs3212227)
and IL-18 -1297 T>C (rs360719) polymorphic variants
was carried out by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP). PCR for
IL12B 3’UTR A>C (rs3212227) was conducted using
the primer pair 5’ TTAAAGACACAACGGAATAGAC
3’and 5’ TGCTTTATCAACACCATCTCC 3’. The PCR-
amplified fragments of IL12B that were 557 bp in length
were isolated and digested with the endonuclease TaqI
(T/CGA) (New England Biolabs, Ipswich, USA). The
IL12B 3’UTR A allele remained uncut whereas the
IL12B 3’UTR C allele was cleaved into 454 bp and
103 bp fragments. PCR for IL-18 -1297 T>C (rs360719)
was conducted using the primer pair 5’ CAACAGT
GATTACAAAGGAAGT 3’ and 5’ TAAATGGGTAG
GAATAAGTGAGA 3’. The PCR-amplified fragments of
IL-18 474 bp in length were digested with endonuclease
NlaIII (CATG/) (New England Biolabs, Ipswich, USA).
The IL-18C allele remained uncut, whereas the IL-18T
allele was cleaved into 295 bp and 179 bp fragments.
DNA digestion products for the IL12B 3'UTR A>C and
IL-18 -1297 T>C polymorphisms were separated by
electrophoresis on 2% agarose gel and visualized by eth-
idium bromide staining. The PCR-RFLP analysis was
repeated for all patient and control samples.
For quality control of the tested polymorphisms, ap-
proximately 10% of the randomly chosen samples were
re-genotyped using commercial sequencing.
Statistical methods
Differences in the distributions of demographic charac-
teristics and selected variables between the examinedgroups were analyzed. The normality of distribution of
variables was checked by the Shapiro-Wilk test. Descrip-
tive statistics are presented as percentage for categorical
variables, as mean with one standard deviation for nor-
mally distributed continuous variables or as median with
range for not normally distributed continuous variables.
The prevalence of variables was assessed by the chi
square (χ2) test or Yates` test, as appropriate. Results
were compared using Student’s t-test for non-paired data
if distribution of variables was normal or the Mann–
Whitney U-test for other than normal distributions.
Hardy-Weinberg equilibrium was tested by a
goodness-of-fit m2 test to compare the observed
genotype frequencies to the expected ones. Power
analysis was conducted employing the Fisher exact
test, which was available at an on-line internet ser-
vice, http://biostat.mc.vanderbilt.edu/twiki/bin/view/
Main/ PowerSampleSize.
The associations between the IL12A, IL12B and IL18
genotypes and risk of impaired anti-HBs development
were estimated by computing the odds ratios (OR) and
their 95% confidence intervals (95% CI) using logistic re-
gression analysis. To address the possibility of a gene-
gene interaction effect between analyzed polymorphisms,
a Multifactor Dimensionality Reduction (MDR) ap-
proach (MDR version 2.0 beta 5) was used [22].
Values of P < 0.05 were judged to be significant.
Ethical issues
This study was approved by the Institutional Review
Board of Poznań University of Medical Sciences, Poland.
Results
The selected demographic, clinical and laboratory data
of groups I (non-responders) and II (responders) are
shown in Table 1. All patients were Caucasian. The
patients in group I were significantly older and had
shorter duration of renal replacement therapy (RRT).
Among the 4 main causes of end-stage renal disease in
groups I and II diabetic nephropathy was the most fre-
quent with the least frequent being chronic glomerulo-
nephritis in group I and chronic tubulointerstitial
nephritis in group II. Significant differences in HBV ser-
omarkers between groups resulted from categorization
of patients to groups I or II.
There was no significant deviation from Hardy-
Weinberg equilibrium in the genotype frequencies in
HD patients of groups I and II (Table 2), and in controls
(Table 3).
The logistic regression analysis (Table 2), performed in
HD patients with a titre of anti-HBs ≤ 10 UI/L (Group I)
or > 10 UI/L (Group II), revealed that a lower frequency of
the rs360719 CC genotype was individually associated with
a significantly increased risk of immune non-responsiveness
Table 1 Data of all patients and of subjects grouped by a titre of antibodies to surface antigen of hepatitis B virus ≤
10 UI/L (Group I) and> 10 UI/L (Group II)
Parameter All patients N= 518 Group I n= 207 Group II n = 311 P value for analysis
between groups I and II
Men, n (% of all) 290 (56.0) 110 (53.1) 180 (57.9) 0.320
Age, years 62.5 ± 15.5 64.8 ± 14.9 60.9 ± 15.8 0.004
RRT duration, years 1.82 (0.002 – 26.1) 1.24 (0.04 – 23.8) 2.71 (0.002 – 26.1) 0.001
Diabetic nephropathy, n (% of all) 141 (27.2) 72 (34.8) 69 (22.2) 0.002
Chronic glomerulonephritis, n (% of all) 86 (16.6) 22 (10.6) 64 (20.6) 0.003
Hypertensive nephropathy, n (% of all) 84 (16.2) 34 (16.4) 50 (16.1) 1.000
Chronic tubulointerstitial nephritis, n (% of all) 60 (11.6) 24 (11.6) 36 (11.6) 1.000
History of acute hepatitis, n (% of all) 23 (4.4) 6 (2.9) 17 (5.5) 0.195
Positive HBsAg, n (% of all) 16 (3.1) 13 (6.3) 3 (1.0) 0.001
Positive HBV DNA, n (% of all HBsAg positive) 16 (100.0)* 13 (100.0) 3 (100.0) 1.000
Positive anti-HBc, n (% of all) 128 (24.7) 30 (14.5) 98 (31.5) < 0.0001
Isolated positive anti-HBc, n (% of all anti-HBc positive) 17 (13.3) 17 (56.7) 0 (0.0) < 0.0001
Full vaccination series against HBV with developed
anti-HBs titre > 10 IU/L in anti-HBc negative patients, n
(% of all anti-HBc negative patients)
213 (54.6) 0 (0.0) 213 (100.0) < 0.0001
Positive anti-HCV, n (% of all) 55 (10.6) 20 (9.7) 35 (11.3) 0.663
Positive HCV RNA (n, % of all examined anti-HCV positive) 32 (58.2) 9 (45.0) 23 (65.7) 0.163
ALT (U/L) 13 (0.6 – 209) 14 (0.6 – 126) 13 (2 – 209) 0.392
AST (U/L) 14 (4 – 177) 14 (5–97) 14.5 (4 – 177) 0.570
GGT (U/L) 27 (0 – 498) 28 (5 – 308) 26 (0 – 498) 0.757
* HBeAg was checked in two HBV DNA positive patients, being on the transplant waiting list, and the results were negative. HBV viral load was determined in
three patients and varied from 4,210 to 1.19E + 09 copies/mL.
Data are expressed as mean ± standard deviation or median and range.
Significant results are indicated using bold font.
Abbreviations: ALT – alanine aminotransferase, anti-HBc – antibodies to core antigen of hepatitis B virus, anti-HBs – antibodies to surface antigen of hepatitis B
virus, anti-HCV – antibodies to hepatitis C virus, AST – aspartate aminotransferase, GGT – gamma-glutamyltranspeptidase, HBeAg – antigen e of hepatitis B virus,
HBsAg – surface antigen of hepatitis B virus, HBV – hepatitis B virus, HBV DNA – deoxyribonucleic acid of hepatitis B virus, HCV RNA – ribonucleic acid of hepatitis
C virus, RRT – renal replacement therapy.
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3.13-fold increased chance to develop anti-HBs in HD
patients (P=0.009). The logistic regression analysis
(Table 3), performed in HD patients with a titre of anti-HBs
≤ 10 UI/L (Group I) and controls, also revealed that a lower
frequency of the rs360719 CC variant was associated with a
significantly (P=0.006) increased risk of immune non-
responsiveness to HBsAg compared with the rs360719 TT
variant.
Selected combined or dichotomized effects of the IL12A
rs568408 3`UTR G>A, IL12B rs3212227 3’UTR A>C
and -1297 T>C (rs360719) IL-18 variants on the develop-
ment of anti-HBs in HD patients are shown in Tables 4
and 5, respectively. A higher frequency of rs360719 CC
combined with rs568408 GG, rs568408 GA or rs568408
GG/AA was associated in HD patients with a significantly
higher chance to develop anti-HBs (P= 0.048, P=0.035
and P= 0.034, respectively) compared to HD patients hav-
ing both wild-type genotypes (rs568408 GG and rs360719
TT). A higher frequency of 360719 CC combined with
rs3212227 AA was also associated with anti-HBs develop-
ment in HD patients (P=0.046) compared to HD patientsbearing both rs3212227 AA and rs360719 TT. Combined
rs568408 AA and rs360719 TT were associated with an
8.94-fold increased risk of non-responsiveness (anti-
HBs < 10 IU/L) (P=0.011) compared to the combined
effects of rs568408 GG and rs360719 TT (Table 4) and
with a 10.85-fold elevated risk of non-responsiveness
(P=0.005) compared to all other genotypes (Table 5).
Combined rs3212227 CC and rs360719 TC were
associated with a 4.61-fold increased risk of non-
responsiveness (P= 0.042) compared to all other geno-
types (Table 5). There were no significant effects of having
the combined rs568408 and rs3212227 variants.
MDR approach revealed a borderline gene-gene inter-
action effect between the analyzed polymorphic variants
of IL12A, IL12B and IL18 in HD patients of both groups
(testing balance accuracy = 0.556, p = 0.094).
Discussion
Vaccination against HBV resulting in the formation of
an anti-HBs titre conferring protection (over 10 IU/L
[20]) was reported in only 54% – 86% of HD patients
using a recombinant vaccine [23-26]. HD patients that
Table 2 IL12 and IL18 polymorphisms in hemodialysis patients with a titre of antibodies to surface antigen of hepatitis
B virus ≤ 10 UI/L (Group I) and> 10 UI/L (Group II)
Variable Group I (n = 207)
n (%)
Group II (n = 311)
n (%)
OR (95 % CI) P value Genotype frequencies (n, %)
expected by Hardy-Weinberg
equilibrium, Group I; Group II
IL12A rs568408
GG 157 (75.8) 220 (70.7) 1.00 152 (73.5); 222 (71.5)
GA 41 (19.8) 86 (27.7) 0.67 (0.44 – 1.02) 0.059 51 (24.4); 81 (26.1)
AA 9 (4.4) 5 (1.6) 2.52 (0.83 – 7.70) 0.094 4 (2.0); 7 (2.4)
GA/AA 50 (24.2) 91 (29.3) 0.77 (0.51 – 1.15) 0.199 P= 0.213; P= 0.783
IL12B rs3212227
AA 129 (62.3) 193 (62.1) 1.00 130 (62.8;) 198 (63.6)
AC 70 (33.8) 110 (35.4) 0.95 (0.65 - 1.38) 0.796 68 (32.9); 100 (32.3)
CC 8 (3.9) 8 (2.6) 1.50 (0.55 - 4.10) 0.433 9 (4.3); 13 (1.4)
AC/CC 78 (37.7) 118 (37.4) 0.99 (0.69 - 1.42) 0.952 P= 0.783; P= 0.421
IL18 rs360719
TT 118 (57.0) 160 (51.4) 1.00 123 (59.4); 160 (51.4)
TC 83 (40.1) 126 (40.5) 0.89 (0.62 – 1.29) 0.544 73 (35.4); 126 (40.5)
CC 6 (2.9) 25 (8.0) 0.32 (0.13 – 0.82) 0.009 11 (5.4); 25 (8.0)
TC/CC 89 (43.0) 151 (48.6) 0.80 (0.56 – 1.14) 0.214 P= 0.330; P= 1.000
A significant result (a sample power 72.7%) is indicated using bold font.
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infection. Natural HBV transmission, if it does not lead
to anti-HBs development, results in:
1. HBsAg carrier status, which is usually associated
with persistent HBV replication (in this study HBV
DNA was detected in all HBsAg positive patients)
and infectivity to other persons,
2. occurrence of isolated anti-HBc positivity (anti-HBc
positive persons are both HBsAg and anti-HBs
negative), which is associated in approximately 8% of
cases with HBV DNA detectable in the blood [27].
Moreover, an anti-HBs titre > 10 IU/L in HD patients
is not always protective against HBV infection and sero-
conversions to anti-HBc positivity, also without clinical
signs of disease, may occur [28].
Prevalence of HBsAg carrier status or isolated anti-
HBc positivity in HD patients varies between individual
HD facilities. As shown in this study, HBsAg carriers
amounted for 3.1% of all HD patients and isolated anti-
HBc positivity occurred in 13.3% of the anti-HBc posi-
tive HD patients. As such frequencies are in the medium
range [26,29-31], these results indicate thousands of
affected HD people worldwide.
The reasons of non-responsiveness to HBsAg are not
fully understood. It has been shown that effective sero-
conversion after vaccination of HD patients depends on
age, body mass, serum albumin concentration, type of
dialyzer, duration of RRT, and underlying kidney disease
[18,32-36]. Such risk factors of non-responsiveness asolder age, shorter RRT duration and diabetic nephropa-
thy were also present in the examined non-responders
compared to responders.
Genetic aspects of responsiveness to HBsAg were also
taken into account, linking responsiveness with the
human leukocyte antigen system [37,38]. More recently,
IL genotypes (IL10, IL-18) were associated with anti-HBs
development in response to HBsAg in HD patients
[18,39].
IL12 and IL18 share biological properties through their
synergism in the promotion of IFN-gamma production
[11-13,40,41]. IL12, generated by macrophages, mono-
cytes, dendritic cells, and B cells, is significantly elevated
in HD patients [42-46], but despite this increase a con-
stitutive IFN-gamma release by peripheral blood
mononuclear cells (PBMCs) of HD patients may be un-
detectable [45]. Plasma levels of free IL18 are also
increased in dialysis patients [47], but Th1 lymphocyte
immunodeficiency was reported owing to the deficit of
IFN-gamma [44,47]. Thereby, genes promoting expres-
sion of these IL may be helpful under specific clinical
conditions. In experimental studies, mice immunized
with an HBV DNA vaccine and the DNA fragments con-
taining the p35 and p40 coding sequences of murine
IL-12 demonstrated increased production of both im-
munoglobulin (Ig) M and IgG anti-HBs titers [5].
Mice vaccinated with a recombinant plasmid carrying the
gene encoding HBsAg linked to a DNA segment encoding
full-length murine IL18 revealed significant serum anti-
HBs IgG response after two intramuscular injections [8].
These effects may be related to the indirect influence of
Table 3 IL12 and IL18 polymorphisms in hemodialysis patients with a titre of antibodies to surface antigen of hepatitis
B virus ≤ 10 UI/L (Group II) and controls
Variable Group I (n = 207)
n (%)
Controls (n = 240)
N (%)




GG 157 (75.8) 171 (71.3) 1.00 171 (71.3)
GA 41 (19.8) 63 (26.3) 0.71 (0.45 – 1.11) 0.131 63 (26.3)
AA 9 (4.4) 6 (2.5) 1.63 (0.57 – 4.71) 0.357 6 (2.5)
GA/AA 50 (24.2) 69 (28.8) 0.79 (0.52 – 1.21) 0.272 P= 1.000
IL12B rs3212227
AA 129 (62.3) 151 (62.9) 1.00 150 (62.3)
AC 70 (33.8) 77 (32.1) 1.06 (0.71 – 1.59) 0.761 80 (33.2)
CC 8 (3.9) 12 (5.0) 0.78 (0.31 – 1.97) 0.597 11 (4.4)
AC/CC 78 (37.7) 89 (37.1) 1.03 (0.70 – 1.51) 0.896 P= 0.950
IL18 rs360719
TT 118 (57.0) 121 (50.4) 1.00 120 (50.2)
TC 83 (40.1) 98 (40.8) 0.87 (0.59 – 1.28) 0.475 99 (41.3)
CC 6 (2.9) 21 (8.8) 0.29 (0.11 – 0.75) 0.006 20 (8.5)
TC/CC 89 (43.0) 119 (49.6) 0.77 (0.53 – 1.11) 0.163 P= 0.950
A significant result (a sample power 78.1 %) is indicated using bold font.
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mediated through the observed increased INF-gamma
production or both. In this study neither the IL12A
rs568408 nor the IL12B rs3212227 polymorphic variants
were individually associated with anti-HBs development
in the examined HD patients as was shown for IL18
rs360719 CC. However, patients bearing the IL18
rs360719 CC genotype had a greater chance to develop
anti-HBs also when occurring concomitantly with the
IL12A rs568408 GG, IL12A rs568408 GA or rs3212227
AA polymorphic variants, but the IL12A rs568408 AA
and IL12B rs3212227 CC variants occurring together with
other than the CC variant of IL18 rs360719 were nega-
tively associated with anti-HBs development.
Liu et al.. [48] using http://pupasuite.bioinfo.cipf.es/,
http://exon.cshl.edu/ESE/ and http://genes.mit.edu/bur-
gelab/rescueese found that rs568408 may disrupt exonic
splicing enhancers. They hypothesized that IL12 mRNA
may be unstable or that IL12 secretion may be lower
due to disrupted exonic splicing, which was suggested as
a functional characterization of IL12A rs568408.
Decreased IL12 secretion results in lower INF-gamma
levels [41]. Liu et al. [48] showed that the IL12A
rs568408 AA and IL12A rs568408 GA/AA genotypes
were more frequent in patients suffering from hepatocel-
lular carcinoma compared to controls. These patients
were HBsAg positive in 73.5% of cases, thereby, near ex-
clusively anti-HBs negative, whereas controls were
HBsAg positive in 12.6% of cases. Although the anti-
HBs titre is not mentioned in the study by Liu et al.
[48], their data directly indicate that A allele of IL12A isassociated with a lack of anti-HBs development. In our
study, HD patients with an anti-HBs titre ≤ 10 IU/L had
a higher frequency of IL12A rs568408 AA in association
with IL18 rs360719 TT than did HD patients with anti-
HBs titre > 10 IU/L. Studies by Sánchez et al. [17] indi-
cate that inhibitory transcription factor OCT-1 binds to
the T allele but not to the C allele at position −1297
(rs360719). The rs360719 T allele was identified as a
possible major repressor site in the IL-18 promoter. This
suppression would result in reduced IL-18 production.
Functional characterization of IL12B rs3212227 3’UTR
A/C is not clear. Morahan et al. [49] observed that the
rs3212227AA genotype was associated with a signifi-
cantly elevated expression of IL12 in Epstein-Barr virus
transformed human cell lines. Similar results were
reported using peripheral lymphocytes: the expression of
the 1159A allele was approximately 50% higher than that
of the 1159 C allele [50]. On the other hand, Seegers
et al. [51] correlated a TaqI polymorphism (C/C) in IL-
12B p40 3`UTR with increased IL-12B p70 secretion by
stimulated monocytes. Additionally, Yilmaz et al. [52]
associated the 1188A/C polymorphism in the 3`UTR of
the IL-12B gene with the expression of IL-12B mRNA
and IL-12B secretion level from lipopolysaccharide (LPS)
and purified protein derivative (PPD) stimulated PBMCs.
Individuals +16974CC homozygous at the IL12B 3'UTR
had significantly higher IL-12 secretion levels from LPS
and PPD stimulated PBMCs than AC heterozygotes or
AA homozygotes [52]. Sánchez et al. [17] found a sig-
nificant increase in the relative expression of IL-18
mRNA in individuals carrying the rs360719 C allele. As
Table 4 The selected combined effects of IL12 and IL18 polymorphisms in hemodialysis patients with a titre of
antibodies to surface antigen of hepatitis B virus ≤ 10 UI/L (Group I) and>10 UI/L (Group II)
Variable Group I
(n = 207) n (%)
Group II
(n = 311) n (%)
OR (95 % CI) P value Sample power (%) for
significant differences
Combined effects of rs568408 and rs360719
rs568408 GG and rs360719 TT 90 (43.5) 115 (37.0) 1.00
rs568408 GG and rs360719 TC 62 (30.0) 88 (28.3) 0.90 (0.59 – 1.38) 0.629
rs568408 GG and rs360719 CC 5 (2.4) 17 (5.5) 0.38 (0.13 – 1.06) 0.048 45.7
rs568408 GG and rs360719 TC/CC 67 (32.4) 105 (33.8) 0.81 (0.54 – 1.23) 0.331
rs568408 GA and rs360719 TT 21 (10.1) 44 (14.1) 0.61 (0,34 – 1.10) 0.095
rs568408 GA and rs360719 TC 19 (9.2) 34 (10.9) 0.71 (0.38 – 1.34) 0.287
rs568408 GA and rs360719 CC 1 (0.48) 8 (2.6) 0.16 (0.02 – 1.32) 0.035 45.3
rs568408 GA and rs360719 TC/CC 20 (9.7) 42 (13.5) 0.61 (0.33 – 1.11) 0.099
rs568408 GA/AA and rs360719 TT 28 (13.5) 43 (13.8) 0.83 (0.48 – 1.45) 0.511
rs568408 GA/AA and rs360719 TC 21 (10.1) 38 (12.2) 0.71 (0.39 - 1,29) 0.252
rs568408 GA/AA and rs360719 CC 1 (0.48) 8 (2.6) 0.16 (0.02 – 1.32) 0.034 45.3
rs568408 GA/AA and rs360719 TC/CC 22 (10.6) 48 (15.4) 0.59 (0.33 – 1.04) 0.064
rs568408 AA and rs360719 TT 7 (3.4) 1 (0.32) 8.94 (1.07 – 74.94) 0.011 65.5
rs568408 AA and rs360719 TC 2 (0.97) 4 (1.3) 0.64 (0.11 – 3.60) 0.602
rs568408 AA and rs360719 CC 0 (0) 0 (0) - -
Combined effects of rs3212227 and rs360719
rs3212227 AA and rs360719 TT 76 (36.7) 102 (32.8) 1.00
rs3212227 AA and rs360719 TC 48 (23.2) 73 (23.5) 0.88 (0.55 – 1.41) 0.602
rs3212227 AA and rs360719 CC 5 (2.4) 18 (5.8) 0.37 (0.13 – 1.05) 0.046 49.4
rs3212227 AA and rs360719 TC/CC 53 (25.6) 91 (29.3) 0.78 (0.50 – 1.23) 0.283
rs3212227 AC and rs360719 TT 40 (19.3) 52 (16.7) 1.03 (0.62 – 1.72) 0.902
rs3212227 AC and rs360719 TC 29 (14.0) 51 (16.4) 0.76 (0.44 – 1.32) 0.328
rs3212227 AC and rs360719 CC 1 (0.48) 7 (2.3) 0.19 (0.02 – 1.61) 0.068
rs3212227 AC and rs360719 TC/CC 30 (14.5) 59 (19.0) 0.68 (0.40 – 1.16) 0.155
rs3212227 AC/CC and rs360719 TT 42 (20.3) 58 (18.6) 0.97 (0.59 – 1.60) 0.910
rs3212227 AC/CC and rs360719 TC 35 (16.9) 53 (17.0) 0.89 (0.52 – 1.49) 0.649
rs3212227 AC/CC and rs360719 CC 1 (0.48) 7 (2.3) 0.19 (0.02 – 1.61) 0.068
rs3212227 AC/CC and rs360719 TC/CC 36 (17.4) 60 (19.3) 0.80 (0.48 – 1.34) 0.403
rs3212227 CC and rs360719 TT 2 (0.97) 6 (1.9) 0.45 (0.09 – 2.30) 0.307
rs3212227 CC and rs360719 TC 6 (2.9) 2 (0.64) 4.03 (0.78 – 20.72) 0.069
rs3212227 CC and rs360719 CC 0 (0) 0 (0) - -
rs3212227 CC and rs360719 TC/CC 6 (2.9) 2 (0.64) 4.03 (0.78 – 20.72) 0.069
Significant results are indicated using bold font.
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CC and IL12B rs3212227 AA were positively associated
with anti-HBs development. In this case, an elevated ex-
pression of IL18 could be accompanied by increased ex-
pression of IL12B. Thereby, our results confirm previous
results indicating that IL12B rs3212227 AA is associated
with elevated IL12 levels [49,50].
It has been discussed that genetic investigations could
help in the development of new and improved vaccines
against HBV and may eventually reduce the proportion
of vaccine failures [53]. It has been shown that the use
of exogenous IL12 as an adjuvant to augment anti-HBsdevelopment in response to vaccines against HBV
[54,55] may help overcome at least some immunologic
deficits of genetic origin. There are also experimental
studies that take advantage of the recombinant plasmid
carrying gene encoding the HBsAg linked to DNA seg-
ment encoding full-length murine IL18 [8]. We have
suggested such a vaccine for non-responders bearing
other IL18 polymorphic variants than −1297 CC
rs360719 [18]. However, at present we are very careful in
our conclusions, because associations that have been
found between polymorphic variants of genes encoding
cytokines may disturb the unique homeostasis between
Table 5 Selected dichotomized effects of IL12A rs568408 and IL18 rs360719 in hemodialysis patients with a titre of
antibodies to surface antigen of hepatitis B virus ≤ 10 UI/L (Group I) and>10 UI/L (Group II)
Variable Group I
(n = 207) n (%)
Group II
(n = 311) n (%)
OR (95 % CI) P value Sample power (%) for
significant differences
Dichotomized genotypes of rs568408 and rs360719
All other genotypes 202 (97.6) 294 (94.5) 1.00
rs568408 GG and rs360719 CC 5 (2.4) 17 (5.5) 0.43 (0.15 – 1.18) 0.080
All other genotypes 185 (89.4) 263 (84.6) 1.00
rs568408 GA/AA and rs360719 TC/CC 22 (10.6) 48 (15.4) 0.65 (0.38 – 1.12) 0.112
All other genotypes 206 (99.5) 303 (97.4) 1.00
rs568408 GA and rs360719 CC 1 (0.48) 8 (2.6) 0.18 (0.02 – 1.49) 0.052
rs568408 GA/AA and rs360719 CC 1 (0.48) 8 (2.6) 0.18 (0.02 – 1.49) 0.052
All other genotypes 200 (96.6) 310 (99.7) 1.00
rs568408 AA and rs360719 TT 7 (3.4) 1 (0.32) 10.85 (1.32 – 89.30) 0.005 75.2
All other genotypes 202 (97.6) 293 (94.2) 1.00
rs3212227 AA and rs360719 CC 5 (2.4) 18 (5.8) 0.40 (0.15 – 1.10) 0.058
All other genotypes 206 (99.5) 304 (97.7) 1.00
rs3212227 AC and rs360719 CC 1 (0.48) 7 (2.3) 0.21 (0.03 – 1.73) 0.084
All other genotypes 206 (99.5) 304 (97.7) 1.00
rs3212227 AC/CC and rs360719 CC 1 (0.48) 7 (2.3) 0.21 (0.03 – 1.73) 0.084
All other genotypes 201 (97.1) 309 (99.4) 1.00
rs3212227 CC and rs360719 TC 6 (2.9) 2 (0.64) 4.61 (0.92 - 23.16) 0.042 52.6
All other genotypes 201 (97.1) 309 (99.4) 1.00
rs3212227 CC and rs360719 TC/CC 6 (2.9) 2 (0.64) 4.61 (0.92 - 23.16) 0.042 52.6
Significant results are indicated using bold font.
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cance of the obtained results cannot yet be declared,
although it does indicate a necessity and implications for
further studies.
There are some limitations of our study which need to
be addressed. The measurement of IL12A, Il12B, IL18
and INF-gamma serum concentrations, especially during
vaccination or natural HBV transmission, was not pos-
sible due to a lack of patient material, although it could
provide further information on mechanisms of anti-HBs
formation in relation to the respective genotypes. An
other limitation of our study is the moderate number of
the examined patients, especially since genetic influences
on responsiveness to HBsAg with anti-HBs development
were shown in homozygotes carrying polymorphic var-
iants of low frequency, which limits the statistical power
of the study. Numerous analyses showed borderline sig-
nificance and were not used to support our conclusion,
as they may indicate the involvement of ILs of the Th1
pathway in the immune response to HBsAg. Therefore,
large population-based studies are warranted to further
elucidate the impact of the examined IL polymorphisms
on anti-HBs development. Finally, we would like to
stress that our results were obtained in Caucasian HD
patients living in the Wielkopolska region of Poland.
Prevalence of rare homozygotes of both IL12 and IL18may vary in other ethnicities. The frequency of the
IL12A rs568408 AA polymorphism in a Chinese control
population was 1.2%, and 18.7% for IL12B rs3212227 CC
[48], whereas in our Caucasian controls the respective
frequencies were 2.5% and 5.0%. Prevalence of IL18
rs360719 CC was 5.7%, 5.5% and 6.1% in Spain, Italy
and Argentina, respectively [17]. In controls from the
South Moravia region (more proximal to Poland), the
IL18 rs360719 CC frequency was 8.0% [56]; in our study
this frequency was 8.8%. The ethnic differences in IL
genotype prevalence may modulate the effect of ILs on
the humoral and cellular immune response, but further
investigations are needed for IL12 and IL18.Conclusions
1. Polymorphisms in IL12A and IL12B may jointly with
IL18 polymorphism contribute to anti-HBs
development in HD patients.
2. In HD patients, the development of anti-HBs is
associated with gene polymorphisms of ILs involved
in the Th1 system.Competing interests
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